miR-590-3p Overexpression Improves the Efficacy of hiPSC-CMs for Myocardial Repair

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS JACC: Basic to Translational Science Pub Date : 2024-05-01 DOI:10.1016/j.jacbts.2023.11.005

Zhiwei Zhang MD , Xiaoting Li MD , Jiawei Zhuang MD , Qingwei Ding MD , Hui Zheng MD , Teng Ma MD , Qingyou Meng MD , Ling Gao PhD

{"title":"miR-590-3p Overexpression Improves the Efficacy of hiPSC-CMs for Myocardial Repair","authors":"Zhiwei Zhang MD , Xiaoting Li MD , Jiawei Zhuang MD , Qingwei Ding MD , Hui Zheng MD , Teng Ma MD , Qingyou Meng MD , Ling Gao PhD","doi":"10.1016/j.jacbts.2023.11.005","DOIUrl":null,"url":null,"abstract":"<div><p>Recent evidence demonstrates that low engraftment rates limit the efficacy of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) for cardiac repair after myocardial infarction. In this study, we attempted to overcome this limitation by enhancing the proliferative capacity of transplanted hiPSC-CMs. We found that miR-590-3p overexpression increased the proliferative capacity of hiPSC-CMs. miR-590-3p overexpression increased the number of engrafted cells and had a higher efficacy for myocardial repair than control cells. Moreover, we confirmed the safety of using miR-590-3p-overexpressing hiPSC-CMs in pig hearts. These results indicated that miR-590-3p overexpression stimulated hiPSC-CM cell cycle re-entry to induce cell proliferation and increased the therapeutic efficacy in MI.</p></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 5","pages":"Pages 557-573"},"PeriodicalIF":8.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X23005193/pdfft?md5=06e86e28db0c5b4549397c70e494adf9&pid=1-s2.0-S2452302X23005193-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X23005193","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Recent evidence demonstrates that low engraftment rates limit the efficacy of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) for cardiac repair after myocardial infarction. In this study, we attempted to overcome this limitation by enhancing the proliferative capacity of transplanted hiPSC-CMs. We found that miR-590-3p overexpression increased the proliferative capacity of hiPSC-CMs. miR-590-3p overexpression increased the number of engrafted cells and had a higher efficacy for myocardial repair than control cells. Moreover, we confirmed the safety of using miR-590-3p-overexpressing hiPSC-CMs in pig hearts. These results indicated that miR-590-3p overexpression stimulated hiPSC-CM cell cycle re-entry to induce cell proliferation and increased the therapeutic efficacy in MI.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

miR-590-3p 过度表达可提高 hiPSC-CMs 修复心肌的疗效

最近的证据表明，低移植率限制了人类诱导多能干细胞衍生的心肌细胞（hiPSC-CMs）在心肌梗死后进行心脏修复的功效。在本研究中，我们试图通过增强移植的hiPSC-CMs的增殖能力来克服这一限制。我们发现，miR-590-3p 的过表达提高了 hiPSC-CMs 的增殖能力，与对照细胞相比，miR-590-3p 的过表达增加了移植细胞的数量，并具有更高的心肌修复功效。此外，我们还证实了在猪心肌中使用过表达 miR-590-3p 的 hiPSC-CMs 是安全的。这些结果表明，miR-590-3p过表达能刺激hiPSC-CM细胞周期重入，诱导细胞增殖，提高对心肌梗死的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.